$ALDX

Class action lawsuit filed against Aldeyra Therapeutics alleging false statements regarding reproxalap clinical trial results. Investors from Nov 2023-Mar 2026 may be eligible.

Rosen Law Firm sues $ALDX over allegedly false reproxalap trial claims. Investors eligible for compensation; lead plaintiff deadline May 29, 2026.

Aldeyra Therapeutics faces federal securities lawsuit alleging inadequate disclosure of failed clinical trial results for reproxalap. Stock crashed 71% after FDA rejection; investor deadline May 29, 2026.

Rosen Law Firm urges $ALDX investors to act before May 29, 2026 deadline in securities class action alleging false reproxalap trial disclosures.

Class action lawsuit filed against $ALDYA alleging false statements about reproxalap clinical trial results. Claims inconsistent data, unreliable findings.

Rosen Law Firm seeks lead plaintiffs in securities class action against Aldeyra Therapeutics over alleged reproxalap trial misstatements. Deadline: May 29, 2026.

Rosen Law Firm alerts Coty investors to May 22, 2026 deadline in securities class action alleging false statements about growth and margins.

Schall Law Firm seeks $ALDX investors for securities fraud lawsuit alleging Aldeyra Therapeutics made false reproxalap drug claims between November 2023-March 2026.

Rosen Law Firm files securities class action against biopharmaceutical company Aldeyra Therapeutics, alleging false statements. Lead plaintiff deadline: May 29, 2026.

Rosen Law Firm filed securities class action against Trip.com over alleged false statements on regulatory risks. Investors have until May 11, 2026 to become lead plaintiffs.

Class action lawsuit filed against Aldeyra Therapeutics alleging false statements about reproxalap clinical trial results, covering investors from November 2023 through March 2026.

Rosen Law Firm files securities class action against Lufax Holding Ltd ($LU), alleging false statements. Investors must act before approaching lead plaintiff deadline.

Rosen Law Firm reminds $ALDX investors of May 29, 2026 deadline to join securities class action alleging false reproxalap trial disclosures.

Class action lawsuit filed against Aldeyra Therapeutics for allegedly false statements on reproxalap trial results, covering investors from November 2023 to March 2026.

Aldeyra Therapeutics faces securities fraud lawsuit alleging it concealed reproxalap trial data inconsistencies, leading to 70.7% stock collapse after FDA rejection in March 2026.

Rosen Law Firm filed class action lawsuit against $ALDX alleging false statements. Investors with $100K+ losses urged to join before deadline.

Rosen Law Firm files securities class action against Trip.com Group Limited ($TCOM), urging investors with losses exceeding $100K to secure counsel before May 11, 2026 deadline.

Schall Law Firm mobilizes class action against Aldeyra Therapeutics for alleged securities fraud tied to reproxalap drug claims. Eligible investors must participate by May 29, 2026.

Rosen Law Firm sues Aldeyra Therapeutics for false reproxalap trial claims. Lead plaintiff deadline: May 29, 2026.

Class action filed against $ALDYA alleging false statements about reproxalap trial results. Eligible investors covered Nov 2023-Mar 2026.